Back to search

Article

In-depth comparative characterization identifies scalable CD123-CAR-NK cells as promising strategy to combat AML

2026-08-25

Abstract excerpt

<title>Abstract</title> <p>Acute myeloid leukemia (AML) is a hematological malignancy characterized by immense heterogeneity, not only between patients but also within malignant populations, leading to limited curative outcomes. These challenges underscore the urgent need for innovative therapies, such as chimeric antigen receptor (CAR)-T cell therapies, which show promising antileukemic activity but remain limit...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
b5534489-4ceb-5f7c-9a2c-140a325afc69
DOI
10.21203/rs.3.rs-10643783/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
In-depth comparative characterization identifies scalable CD123-CAR-NK cells as promising strategy to combat AMLDOI 10.21203/rs.3.rs-10643783/v1
Automated and closed clinical-grade manufacturing protocol produces potent NK cells against neuroblastoma cells and AML blastsSemantic proximity
Adoptive NK cell therapy in AML: progress and challengesSemantic proximity
Current status and perspective of CAR-T and CAR-NK cell therapy trials in GermanySemantic proximity
Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in Acute Myeloid LeukemiaSemantic proximity
An integrated multi-omics investigation of W-NK1, a cytokine-primed non-engineered natural killer cell therapy productSemantic proximity
Engineering CAR-NK cells to secrete IL15 sustains their anti-AML functionality, but is associated with systemic toxicitiesSemantic proximity
CD33 <sup>KO</sup> -CD33-mesothelin loop CAR design avoids fratricide and improves efficacy of iNK cells against acute myeloid leukemiaSemantic proximity
Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.Semantic proximity
Chimeric antigen receptor-natural killer cell therapy: current advancements and strategies to overcome challengesSemantic proximity
CAR<sup>+</sup> and CAR<sup>-</sup> T cells differentiate into an NK-like subset that is associated with increased inflammatory cytokines following infusionSemantic proximity
Engineering CAR-NK cells targeting CD33 with concomitant extracellular secretion of anti-CD16 antibody revealed superior antitumor effects toward myeloid leukemiaSemantic proximity
Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemiaSemantic proximity
Select a neighboring publication to make it the new centre.